CA2561904A1 - Mitotic kinesin inhibitors - Google Patents

Mitotic kinesin inhibitors Download PDF

Info

Publication number
CA2561904A1
CA2561904A1 CA002561904A CA2561904A CA2561904A1 CA 2561904 A1 CA2561904 A1 CA 2561904A1 CA 002561904 A CA002561904 A CA 002561904A CA 2561904 A CA2561904 A CA 2561904A CA 2561904 A1 CA2561904 A1 CA 2561904A1
Authority
CA
Canada
Prior art keywords
compound
group
alkyl
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002561904A
Other languages
English (en)
French (fr)
Inventor
Weibo Wang
Ryan Constantine
Liana Lagniton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2561904A1 publication Critical patent/CA2561904A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002561904A 2004-04-06 2005-04-06 Mitotic kinesin inhibitors Abandoned CA2561904A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56023504P 2004-04-06 2004-04-06
US60/560,235 2004-04-06
PCT/US2005/011642 WO2005100357A1 (en) 2004-04-06 2005-04-06 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
CA2561904A1 true CA2561904A1 (en) 2005-10-27

Family

ID=34964986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002561904A Abandoned CA2561904A1 (en) 2004-04-06 2005-04-06 Mitotic kinesin inhibitors

Country Status (15)

Country Link
US (3) US20080249112A1 (https=)
EP (1) EP1732926B1 (https=)
JP (1) JP4895220B2 (https=)
KR (1) KR20060135035A (https=)
CN (1) CN1984912A (https=)
AT (1) ATE419249T1 (https=)
AU (1) AU2005233576A1 (https=)
BR (1) BRPI0509653A (https=)
CA (1) CA2561904A1 (https=)
DE (1) DE602005012069D1 (https=)
ES (1) ES2318478T3 (https=)
PL (1) PL1732926T3 (https=)
PT (1) PT1732926E (https=)
RU (1) RU2006138864A (https=)
WO (1) WO2005100357A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
KR101170925B1 (ko) * 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
RU2007106552A (ru) * 2004-07-22 2008-08-27 Астразенека Аб (Se) Конденсированные пиримидоны, пригодные для лечения и предотвращения злокачественного новообразования
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CN101027309B (zh) * 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
AU2007323998B2 (en) * 2006-11-13 2011-09-22 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
AU2008205169B2 (en) * 2007-01-05 2012-02-02 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
CA2485148A1 (en) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2004113335A2 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin

Also Published As

Publication number Publication date
US20050228002A1 (en) 2005-10-13
JP2007532554A (ja) 2007-11-15
RU2006138864A (ru) 2008-05-20
US7504405B2 (en) 2009-03-17
JP4895220B2 (ja) 2012-03-14
CN1984912A (zh) 2007-06-20
ATE419249T1 (de) 2009-01-15
US20090171082A1 (en) 2009-07-02
AU2005233576A1 (en) 2005-10-27
BRPI0509653A (pt) 2007-10-09
ES2318478T3 (es) 2009-05-01
EP1732926B1 (en) 2008-12-31
US20080249112A1 (en) 2008-10-09
PL1732926T3 (pl) 2009-06-30
WO2005100357A1 (en) 2005-10-27
DE602005012069D1 (de) 2009-02-12
PT1732926E (pt) 2009-04-03
KR20060135035A (ko) 2006-12-28
EP1732926A1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
US20090171082A1 (en) Mitotic kinesin inhibitors
US7855295B2 (en) Tetrahydrocarboline compounds as anticancer agents
JP4778439B2 (ja) 抗癌剤としてのキナゾリノン化合物
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
US7345046B2 (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
JP5036002B2 (ja) ２−アミノ−７，８−ジヒドロ−６Ｈ−ピリド［４，３−ｄ］ピリミジン−５−オン
JP2019085414A (ja) Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤
MXPA05005477A (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
JP2007512368A5 (https=)
EA030451B1 (ru) Ингибиторы гистондеметилаз
US20070027150A1 (en) 2-Amino-quinazolin-5-ones
WO2016115869A1 (zh) Flt3激酶的新型抑制剂及其用途
CN102911157A (zh) (e)-3-[2-溴-5-(3-取代丙氧基)]苯基-n-{4-甲基-3-[4-(吡啶-3-基)嘧啶-2-基]氨基}苯基丙烯酰胺类化合物
MXPA06011464A (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued